SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for pivotal extended Phase 3 data for CAN-2409, with the community closely monitoring the upcoming plenary presentation for evidence of practice-changing efficacy in prostate cancer. Market participants are actively discussing the stock's significant institutional support, potential for a premium buyout by Big Pharma, and the ongoing tension between optimistic long-term holders and aggressive short-selling activity.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors pivot from story-driven AI names to companies with verifiable semiconductor revenue, with many drawing favorable valuation comparisons to industry peers despite its smaller market cap. The community is actively discussing its potential for a re-rating, fueled by expanding AI and EV testing demand and a lean share structure that amplifies volatility.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as the community actively discusses the stock's recent GPO partnership and potential for commercial traction, while weighing these developments against persistent concerns regarding management's history of dilution and the company's capital burn. Investors are closely monitoring weekly prescription data and upcoming earnings reports, debating whether current commercial progress justifies the stock's valuation or indicates continued financial instability.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors aggressively debate whether the current price represents a deep-value accumulation opportunity or a value trap, with community sentiment split between frustration over persistent share price weakness and conviction in the company's pivot toward agentic AI orchestration. Traders are closely monitoring a high level of short interest and significant institutional accumulation, viewing upcoming earnings as a critical catalyst to potentially break the stock out of its long-standing consolidation phase.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant investor attention following a robust quarterly performance that exceeded revenue and profit expectations, driven by the strong adoption of its oral Wegovy GLP-1 therapy. The community is actively discussing this momentum as a potential reversal of previous growth concerns, while also tracking high-volume prescription data and competitive dynamics against Eli Lilly.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to strong earnings and raised EBITDA guidance, while the community actively discusses the stock's significant long-term growth potential and its strategic importance in the ongoing global LNG supply disruption. Traders are closely monitoring the impact of Middle East geopolitical tensions and potential price target upgrades as they anticipate a breakout beyond current resistance levels.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is capturing significant attention as investors react to a new joint venture between major U.S. carriers, fueling community debate over the companys strategic positioning against competitors like SpaceX. The stock remains a focal point for intense volatility, with ongoing discussions centered on upcoming launch catalysts, institutional buying activity, and whether the company's patented direct-to-device technology can successfully scale into a dominant market share.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge is experiencing significant market volatility driven by speculative options trading and broader energy sector reactions to shifting geopolitical tensions and AI-driven data center demand. Investors remain sharply divided, with a vocal community debating the stock's long-term turnaround potential versus concerns over sustained cash burn and competitive pressure.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating intense market discussion following a strategic pivot into high-density power solutions for AI data centers and a series of product rollouts, including its new solid-state transformer platform. While the solar sector faces ongoing macro headwinds and cyclical demand challenges, the community is actively debating whether these infrastructure-focused innovations will serve as a fundamental re-rating catalyst for the stock.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing intense volatility and heavy algorithmic manipulation despite reporting strong earnings and growth metrics that have led analysts to maintain high price targets. The community is actively debating the stock's disconnect between its robust fundamental performance and its erratic price swings, with many investors viewing the current price action as a strategic shakeout by institutional players ahead of potential platform catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Leerink said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.</li><li>Mizuho raised its price target for TNGX to $30 from $20 and maintained an ‘Outperform’ rating, citing stronger front-line pancreatic cancer revenue expectations.</li><li>Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating, citing recent financing activity and progress in vopimetostat development.</li></ul>Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.Despite the first-quarter (Q1) miss, analysts at Leerink nearly doubled their price target for TNGX stock on Friday, according to TheFly.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TNGX">Tango Therapeutics shares</a> were headed for their worst single-day fall in more than 19 months.<h2 class="st-heading-2">Leerink, Mizuho, Wedbush Turn Bullish On TNGX</h2>Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating after the company’s Q1 results and pipeline update.The firm said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.Leerink also backed Tango’s decision to prioritize first-line pancreatic cancer studies combining vopimetostat with RAS(ON) inhibitors over a standalone second-line trial.Analysts at Mizuho raised their price target on Tango Therapeutics to $30 from $20, while keeping an ‘Outperform’ rating. The firm cited increased front-line pancreatic ductal adenocarcinoma revenue assumptions for the target boost.Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating. The analysts cited the company’s recent financing activity and progress in the development of vopimetostat.However, analysts at Piper Sandler downgraded TNGX stock to ‘Neutral’ from ‘Overweight’, but hiked the price target to $24 from $16. The firm stated that it has become less confident in vopimetostat following the company’s shift away from its previously disclosed monotherapy strategy.<h2 class="st-heading-2">TNGX Q1 At A Glance</h2>Tango Therapeutics reported adjusted loss per share of $0.32 in Q1, compared to a loss of $0.36 per share during the same period a year ago. Revenue was nil for the quarter, compared with $5.4 million in the year-ago period.Wall Street expected Tango Therapeutics to report a loss of $0.31 per share on revenue of $0.58 million, according to Fiscal.ai data.The company stated that it had recognized all remaining deferred revenue tied to upfront and research option-extension payments under its Gilead collaboration in fiscal year 2025, after the agreement was terminated and all research activities had concluded.<h2 class="st-heading-2">TNGX Provides Update On Upcoming Milestones</h2>The company expects to report initial Phase 1/2 safety and efficacy data in 2026 for vopimetostat combination trials with daraxonrasib and Revolution Medicines’ zoldonrasib.It also plans to provide a lung cancer update from its vopimetostat monotherapy study this year, along with the release of early Phase 1/2 data from the TNG456 monotherapy trial this year.Additionally, the company aims to begin a Phase 1/2 combination study of vopimetostat and Erasca’s ERAS-0015 in the second half of 2026.<h2 class="st-heading-2">How Did Retail Traders React To TNGX?</h2>Retail sentiment on Stocktwits around Tango Therapeutics trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/TNGX">TNGX stock</a> is up 120% year-to-date and 1,182% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 34% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 68%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apollo-torsten-slok-inflation-very-serious-fed-rate-hike-kevin-warsh-powell/cZXmcm4RekG">Apollo’s Torsten Slok Warns Inflation Has Become A ‘Very Serious’ Problem — Says Markets Now Expect Fed Rate Hikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tango Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.

Equity

Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating.

IWM, BE, STRL, FN: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 ETF (Symbol: IWM) where we have detected an...

<ul class="summary-bullets"><li>The hold follows the company’s earlier voluntary pause in late February 2026, triggered by reversible cardiac observations seen at supratherapeutic doses in a healthy volunteer study.</li><li>Aardvark now plans to unblind the clinical data accumulated to date for ARD-101 to assess the full efficacy and safety profile.</li><li>The company also said that it will continue to engage with the FDA on the path forward for its lead candidate.</li></ul>Aardvark Therapeutics (AARD) shares tumbled 17% in after-hours trading on Thursday, after the company disclosed that the U.S. Food and Drug Administration has placed a full clinical hold on its lead candidate ARD-101.Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in Prader-Willi Syndrome patients and the associated open-label extension (OLE) study. The hold follows the company’s earlier voluntary pause in late February 2026, triggered by reversible cardiac observations seen at supratherapeutic doses in a healthy volunteer study.<h2 class="st-heading-2">AARD’s Next Steps</h2>“We are continuing to work collaboratively with the agency to comprehensively evaluate the data and determine the best path forward for ARD-101,” said CEO Tien Lee while reiterating commitment to patient safety.In parallel with FDA discussions, Aardvark plans to unblind the clinical data accumulated to date for ARD-101 to assess the full efficacy and safety profile and inform next steps. As of late February, 87 patients have been dosed in the two trials, the company said.ARD-101 is an oral small-molecule aimed at addressing hyperphagia—the insatiable hunger characteristic of PWS, a rare genetic disorder. This latest development adds to the uncertainty around the ARD-101 program, which had already seen its late-stage topline results delayed. The company was previously expecting to release topline data in the third quarter of 2026, but scrapped that timeline after the voluntary pause imposed in February. No fresh timeline has been issued so far.The company reported a solid cash position of $91.2 million as of March 31, 2026, which it believes is sufficient to fund operations into mid-2027.<h2 class="st-heading-2">How Did AARD Retail Traders React?</h2>On Stocktwits, retail sentiment around AARD stock stayed within the ‘neutral’ territory while message volume remained at ‘high’ levels.According to data from Koyfin, eight of the 12 analysts covering AARD rate it ‘Buy’ while four rate it ‘Hold.’ The 12-month average price target on the stock is $16.70, representing a potential upside of about 148%.Earlier this week, Bank of America lowered its price target on AARD to $18 from $20 while retaining its ‘Buy’ rating on the stock after the firm released its first quarter report, wherein it said that it will provide further guidance on its ARD-101 and ARD-201 programs in the second quarter. The company placed a voluntary pause on ARD-201 in March, as it is a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor being studied for weight loss and weight regain prevention.<a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has fallen 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pzza-stock-rallies-after-hours-on-report-of-largest-us-franchisee-joining-1.5billion-buyout-push/cZXS5XnReSK">PZZA Stock Rallies After Hours On Report Of Largest US Franchisee Joining $1.5B Buyout Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program

Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.

<ul class="summary-bullets"><li>REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, raising cash concerns.</li><li>Cash, cash equivalents, and marketable securities stood at $150.5 million at Q1-end, which the firm expects to be sufficient to fund its operations into early 2027.</li><li>Both Q1 revenue and earnings fell short of Wall Street expectations on Thursday.</li></ul>Shares of REGENXBIO Inc. (RGNX) dropped 37% on Thursday after the company reported disappointing first-quarter 2026 (Q1) financial results that overshadowed positive pivotal late-stage trial data for its lead Duchenne muscular dystrophy candidate RGX-202.The stock is on track for its worst day ever, if losses hold.<h2 class="st-heading-2">RGNX’s Q1 Earnings</h2>The company reported that revenue for the three months ended March 31 plunged to $6.4 million from $89.0 million a year earlier, and below an analyst estimate of $25.25 million. The steep decline was driven by the absence of a $70 million upfront license payment recognized in Q1 2025 under the Nippon Shinyaku collaboration and lower royalties from Novartis’ ZOLGENSMA after U.S. patent expiration in January 2026.REGENXBIO swung to a net loss of $90.1 million, or $1.72 per share, compared with net income of $6.1 million, or $0.12 per share, in the prior-year quarter. Wall Street, on average, had estimated a loss of only $1.3/ share.Cash, cash equivalents, and marketable securities stood at $150.5 million at quarter-end, which the firm expects to be sufficient to fund its operations into early 2027.<h2 class="st-heading-2">DMD Trial Readout</h2>In a separate announcement, REGENXBIO reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness, primarily affecting young boys.The study met its main goal. Ninety-three percent of patients produced high levels of the needed muscle protein after 12 weeks, averaging 71%.One-year data from some patients showed meaningful improvements in movement and muscle function compared to untreated boys. The treatment was generally safe, with two serious side effects that resolved, Regenxbio said.The results support plans for an accelerated approval filing and subsequent launch in 2027, the firm said. REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, which could add uncertainty to the timeline, though the company remains optimistic and plans further FDA discussions.<h2 class="st-heading-2"> How Did RGNX Retail Traders React?</h2>On Stocktwits, retail sentiment around RGNX stock increased from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed hopes for the stock recovering after the “overreaction.” The user sees the company’s market cap touching $1 billion in time, up from its current near $330 million market cap now.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/653352403</stembedurl>Another user expressed hopes for Novartis buying the company.<stembedurl>https://www.stocktwits.com/murphylaw/message/653377645</stembedurl>Another user highlighted that the company doesn’t seem to have enough cash to conduct another trial if the FDA insists.<stembedurl>https://www.stocktwits.com/Find_the_Cure/message/653359896</stembedurl><a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has fallen by about 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa">IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regenxbio logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.

The Battle of iShares ETFs: Should You Buy the S&P 500 ETF or Russell 2000?

Key PointsiShares Core S&P 500 ETF provides lower-cost exposure to large-cap equities with an expense ratio of 0.03% compared to 0.19% for iShares Russell 2000 ETF...

<ul class="summary-bullets"><li>Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.</li><li>Omeros is now awaiting a European Medicines Agency decision on the Yartemlea marketing authorization application.</li></ul>Omeros Corporation (OMER) shares rose more than 4% in after-hours trading on Wednesday after the company reported its first quarter of commercial revenue from the U.S. launch of YARTEMLEA for transplant-associated thrombotic microangiopathy (TA-TMA).Omeros posted first-quarter net product sales of $9.9 million, compared with zero in the year-ago period when the drug was not yet approved or launched, and above an estimated $4.11 million. Adjusted net loss narrowed to $0.24 per share, compared to a loss of $0.58 in the corresponding quarter of last year, and below a loss of $0.29 expected by Wall Street analysts.The company ended the quarter with $135.3 million in cash, cash equivalents, and short-term investments. Operating expenses fell sharply to $27.3 million from $35.0 million a year earlier, driven mainly by lower research and development spending after the earlier sale of the firm’s experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion.“The launch of YARTEMLEA has changed the trajectory of Omeros, both operationally and financially. We are seeing strong early adoption across transplant centers, expanding formulary access, favorable reimbursement support, and growing physician experience with the first and only approved treatment for TA-TMA,” CEO Gregory A. Demopulos said. Omeros launched Yartemlea in the U.S. in January for TA-TMA, or a severe, often fatal complication of bone marrow transplantation.Omeros also noted several upcoming catalysts, including a European Medicines Agency decision on the YARTEMLEA marketing authorization application expected in mid-2026. The company continues to advance its broader pipeline, including OMS527 for cocaine use disorder, and T-CAT programs targeting multidrug-resistant pathogens.<h2 class="st-heading-2">How Did OMER Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user opined that the after-hours price action does not justify the company’s “great” earnings call.<stembedurl>https://www.stocktwits.com/jmmoore4/message/653300780</stembedurl>Another user said that they see the stock climbing to $20 as the EMA decision nears and further to $100 in time.<stembedurl>https://www.stocktwits.com/MayorofMNKD/message/653296248</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has more than tripled in value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/envx-stock-tumbles-after-hours-on-smartphone-battery-qualification-timeline-concerns/cZXLUN5ReKA">ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations  

Yartemlea net sales in Q1 came in at $9.9 million, higher than the $4.1 million expected by Wall Street. 

<ul class="summary-bullets"><li>Talluri acknowledged that the qualification process has taken longer than expected.</li><li>He further noted encouraging results in energy density, fast charging, and safety, with longer-term cycle-life testing still ongoing.</li><li>The company provided second-quarter guidance of $8.0 million to $9.0 million in revenue and adjusted net loss per share of $0.13 to $0.17.</li></ul>Shares of Enovix Corporation (ENVX) fell 12% after hours on Wednesday, as investors appeared disappointed by the firm’s smartphone battery qualification timelines despite first-quarter earnings beating Wall Street expectations.The silicon battery cell maker’s CEO Raj Talluri said smartphones remain the company’s top priority as it works to finish qualification with its lead customer and prepare for commercial production in the demanding consumer electronics market.The company has reached a key milestone by agreeing with its lead smartphone customer on a new testing framework designed specifically for its silicon batteries. Talluri added that the second smartphone customer also agrees that the old industry testing standard is not suitable for silicon technology, and the two sides are discussing a replacement framework.Talluri acknowledged that the qualification process has taken longer than expected. He further noted encouraging results in energy density, fast charging, and safety, with longer-term cycle-life testing still ongoing. Beyond smartphones, the company’s defense business continues to show strong commercial momentum, and its battery for smart eyewear has entered early production, Talluri said.<h2 class="st-heading-2">ENVX Q1 Earnings</h2>On Wednesday, Enovix reported first-quarter 2026 revenue of $7.6 million, a 49% increase from $5.1 million in the year-ago period, driven by higher shipments in defense and industrial markets.Adjusted net loss was $0.14 per share in the quarter versus $0.13 per share in the prior-year quarter and below an estimated loss of $0.19. Enovix ended the quarter with $582.7 million in cash, cash equivalents, and marketable securities.<h2 class="st-heading-2">Looking Ahead</h2>The company provided second-quarter guidance of $8.0 million to $9.0 million in revenue, in line with an expected $8.57 million, and adjusted net loss per share of $0.13 to $0.17, lower than the loss of $0.20 expected by Wall Street. Capital expenditures are expected to range between $9.0 million and $13.0 million, the firm said.<h2 class="st-heading-2">How Did ENVX Retail Traders React?</h2>On Stocktwits, retail sentiment around ENVX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed disappointment over the delays in the smartphone testing segment but highlighted that the company also made “some real progress.”<stembedurl>https://www.stocktwits.com/ointhebay/message/653292246</stembedurl>Another user highlighted that the company is catering to multiple industries instead of relying on just the smartphone business.<stembedurl>https://www.stocktwits.com/Stingraystev/message/653292506</stembedurl><a href="https://stocktwits.com/symbol/ENVX">ENVX stock</a> has fallen 8% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-stock-draws-attention-as-culper-research-takes-short-position-over-china-ties/cZXLrSBReKF">Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Enovix Corporation.

ENVX Tumbles After Hours On Smartphone Battery Qualification Timeline Concerns

The battery cell maker’s CEO Raj Talluri said smartphones remain the company’s top priority.

<ul class="summary-bullets"><li>Integrated memory revenue rose 53% year-on-year to $308 million in H1 FY2026, accounting for roughly 45% of Penguin Solutions’ total revenue of $686 million during the period.</li><li>Penguin Solutions stated that the next phase of AI will focus on inference rather than training.</li><li>The company said its products are designed to help customers optimize token economics and scale inference workloads efficiently.</li></ul>Shares of Penguin Solutions Inc. (PENG) were up more than 20% in Wednesday’s pre-market trade, on track for their best single-day gains in about 22 months.The company stated on Tuesday that its AI-driven business accounted for more than 60% of total sales during the first half of fiscal year 2026, up more than 50% year over year.<h2 class="st-heading-2">PENG Banks On Agentic AI Boom</h2>Penguin Solutions stated that the next phase of AI will focus on inference rather than training. The company said its products are designed to help customers optimize token economics and scale inference workloads efficiently.Penguin stated that inference aligns with its expertise in building customized high-performance AI infrastructure tailored to specific customer workloads.Integrated memory revenue rose 53% year-on-year to $308 million in H1 FY2026, accounting for roughly 45% of Penguin Solutions’ total revenue of $686 million during the period.<h2 class="st-heading-2">Rosenblatt Says PENG’s Expansion Plans Are Impressive</h2>According to TheFly, Rosenblatt analysts said that Penguin Solutions CEO Kash Shaikh’s strategy to build on the company’s more than 40 years of memory-subsystem expertise is compelling.The analysts added that the company is combining that foundation with AI software and services to deliver a full-stack platform solution.Rosenblatt raised its price target for PENG stock to $54 from $32, while keeping a ‘Buy’ rating. The firm noted that the higher price target reflects rising demand for optimized memory subsystems in the AI market, as well as faster corporate adoption of internal AI systems driven by agentic AI.<h2 class="st-heading-2">PENG Says AI Moving From Pilots To Deployment</h2>According to the firm, AI is now moving beyond pilots to full-on-premises deployments, and demand is broadening from hyperscalers to enterprises and sovereign customers. The demand for memory is increasing as AI workflows move into production at scale.The company also highlighted that its integrated memory modules are built into the infrastructure platforms of industry leaders, which include Alphabet Inc.’s (GOOG, GOOGL) Google, Intel Corp. (INTC), and Juniper Networks, among others.<h2 class="st-heading-2">What Does PENG Do?</h2>Penguin Solutions is a Fremont, California-based company that provides memory and AI infrastructure designed to support enterprises, sovereign AI projects, and neocloud providers.The company offers a full-stack platform comprising hardware and software solutions to help customers deploy and scale AI workloads while optimizing their total cost of ownership.<h2 class="st-heading-2">How Did Retail Traders React To PENG?</h2>Retail sentiment on Stocktwits around Penguin Solutions trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/PENG">PENG stock</a> is up 126% year-to-date and 133% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 36% over the past 12 months, while the iShares Core S&amp;P Small-Cap ETF (IJR) is up 26%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/googl-spacex-reportedly-in-talks-to-launch-data-centers-in-orbit-spacex-ipo/cZXXjlVReio">Google, SpaceX Reportedly In Talks To Launch Data Centers In Orbit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Penguin Solutions logo is seen displayed on a smartphone screen

PENG Stock Heads For Best Single-Day Gains In 22 Months — Penguin Says AI-Driven Business Now Accounts For 60% Of H1 Revenue

Penguin Solutions reported that its AI-driven business revenue soared by more than 50% year over year in the first half of fiscal year 2026.

<ul class="summary-bullets"><li>The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001 &nbsp;in heavily pretreated patients with chronic-phase chronic myeloid leukemia.</li><li>Enliven is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.</li><li>Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.</li></ul> Shares of Enliven Therapeutics (ELVN) jumped 7% on Tuesday after the company announced that it will present positive data on its lead candidate at an upcoming conference on the heels of a Wall Street push for its experimental cancer drug.Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm next month.<h2 class="st-heading-2">Key Trial Data</h2>The new results from the ongoing ENABLE trial, based on a December 22, 2025, data cutoff, showed encouraging efficacy and a favorable safety profile for ELVN-001 &nbsp;in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CML). Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.As of the cutoff, 141 patients had been enrolled across dose levels, with 76% remaining on treatment and a median treatment duration of 31.7 weeks, the company said.“As we treat more patients and extend follow-up, ELVN-001 continues to demonstrate robust anti-CML activity in a heavily pretreated patient population,” said Helen Collins, chief medical officer of Enliven. “These results are consistent with our earlier findings demonstrating a favorable safety and tolerability profile, reinforcing ELVN-001’s highly selective design.”The oral presentation is scheduled for June 11, 2026. Enliven, a clinical-stage biopharmaceutical company focused on small molecule therapeutics, is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026.<h2 class="st-heading-2">Wall Street Push</h2>Separately, Guggenheim Securities initiated coverage of Enliven late Monday with a ‘Buy’ rating and an $80 price target.The firm described ELVN-001 as a “potential best-in-class” oral therapy for CML that is expected to be late-stage-ready this summer.Analysts noted that Enliven’s current valuation does not fully reflect the size of the commercial opportunity, strategic validation, or reasonable risk-adjusted market share assumptions for the drug.Last week, Goldman Sachs raised its price target on Enliven to $59 from $41 and kept a ‘Buy’ rating on the shares, while highlighting broader competitive and industry signals, including Merck's (MRK) recent acquisition of Terns Pharmaceuticals, which underscore increasing biopharma interest in the CML space and reinforce Enliven's strategic attractiveness.In March, Clear Street also termed ELVN-001 a lower-risk, high-upside asset.According to data from Koyfin, all nine analysts covering Enliven rate it ‘Buy.’ The 12-month average price target on the stock is $57, representing a potential upside of about 44% from its last closing price.<h2 class="st-heading-2">How Did ELVN Retail Traders React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-spacex-merger-ron-baron-throws-support-behind-elon-musk-potential-move/cZXXjXNReiF">Tesla-SpaceX Merger Speculation: Ron Baron Throws Support Behind Elon Musk’s Potential Move</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil

Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm. 

<ul class="summary-bullets"><li>D-Wave Quantum reported $15 million in revenue during the same period a year ago.</li><li>The company stated that its Q1 2025 revenue included a $12.6 million sale of an Advantage annealing quantum computer, with the remaining $2.4 million from regular business rather than a one-time sale.</li><li>D-Wave Quantum reported a 1,994% YoY surge in Q1 bookings to $33.4 million, up from $1.6 million a year earlier.</li></ul>D-Wave Quantum Inc. (QBTS) shares tumbled on Tuesday morning after the company reported its first-quarter earnings, citing an 81% decline in revenue.D-Wave Quantum reported a loss of $0.05 per share on revenue of $2.9 million, compared to Wall Street estimates of a loss of $0.08 per share on revenue of $4.14 million, according to Fiscal.ai data.<a href="https://stocktwits.com/symbol/NVDA">D-Wave shares</a> were down nearly 7% in Tuesday’s pre-market trade. QBTS was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">QBTS Revenue Tanks 81% YoY</h2>D-Wave Quantum’s Q1 revenue of $2.9 million not only fell short of Wall Street estimates, but it also declined 81% YoY from $15 million during the same period a year ago.The company stated that the year-ago period’s revenue included a $12.6 million sale of an Advantage annealing quantum computer, with the remaining $2.4 million from regular business rather than a one-time sale.During the same quarter in 2024, D-Wave Quantum’s revenue stood at $2.5 million.<h2 class="st-heading-2">QBTS Reports 1994% Jump In Bookings</h2>D-Wave Quantum reported a massive surge of 1,994% year-on-year in bookings during the first quarter. The company stated that bookings totaled $33.4 million, up from $1.6 million in the same period a year ago.D-Wave stated that Q1 bookings include a $20 million agreement with Florida Atlantic University to install an Advantage2 annealing quantum computer at its Boca Raton campus.The company stated that the deployment of the quantum computer is expected later in the year. D-Wave Quantum also launched a training program at Florida Atlantic University to help faculty integrate quantum resources into research and coursework, with system installation expected to begin before the end of 2026.<h2 class="st-heading-2">QBTS Signs 2-Year Agreement With Fortune 100 Company</h2>The company also stated that it signed a two-year Quantum Computing as a Service (QCaaS) agreement with a Fortune 100 company. The agreement is worth $10 million.Together, these two bookings account for about 90% of D-Wave Quantum’s bookings during the quarter. The company stated that it will recognize revenue from these bookings in subsequent quarters.“Our acquisition of Quantum Circuits is expected to meaningfully accelerate our delivery of a scalable, error-corrected gate model system, while our record-setting $10 million quantum computing as a service agreement with a Fortune 100 company reinforced growing demand for our annealing systems,” said D-Wave Quantum CEO Alan Baratz.<h2 class="st-heading-2">How Did Retail Traders React To QBTS?</h2>Retail sentiment on Stocktwits around QBTS trended in the ‘bullish’ territory, with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/QBTS">QBTS stock</a> is down 8% year-to-date, but up 117% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 42% over the past 12 months, while the Vanguard Total Stock Market Index Fund ETF (VTI) is up 31%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/se-stock-soars-despite-mixed-q1-ceo-says-significant-growth-ahead/cZXX9ziReLz">Sea Delivers A Mixed Q1, CEO Highlights Improving Unit Economics — 'Significant Runway For Growth Still Ahead Of Us'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

D-Wave Systems Inc. logo of a Canadian quantum computing company is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

QBTS Stock Gets A Thumbs Down From Investors After 81% Revenue Decline – But Bookings Soar By A Whopping 1994%

D-Wave Quantum reported a loss of $0.05 per share on revenue of $2.9 million, compared to Wall Street estimates of a loss of $0.08 per share on revenue of $4.14 million.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest IWM News

IWMiShares Russell 2000 ETF